MARK2 and lung cancer: Xu et al., evaluated the effects of combining baicalin and cisplatin (DPP) on the proliferation of A549 and A549/DPP (DPP-resistant) human lung cancer cells by MTT assay, and suggested that baicalin exerted synergistic anti-tumor effects by reversing the resistance of lung cancer to cisplatin, and the underlying mechanism was related to the down-regulation of both Microtubule affinity-regulating kinase 2 (MARK2) and p-AKT [34].